Sarepta Therapeutics (NASDAQ:SRPT) Trading 5.5% Higher

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) traded up 5.5% during trading on Tuesday . The stock traded as high as $100.70 and last traded at $99.95, 2,845,300 shares traded hands during mid-day trading. An increase of 107% from the average session volume of 1,372,377 shares. The stock had previously closed at $94.78.

Several analysts have recently commented on the stock. HC Wainwright set a $160.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Friday, September 13th. Janney Montgomery Scott lowered their price target on shares of Sarepta Therapeutics from $200.00 to $175.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Piper Jaffray Companies set a $185.00 price target on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Friday, September 27th. Morgan Stanley lowered their price target on shares of Sarepta Therapeutics from $220.00 to $160.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Finally, Credit Suisse Group lowered their price target on shares of Sarepta Therapeutics from $201.00 to $185.00 and set an “outperform” rating on the stock in a research report on Friday. Two investment analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $187.78.

The company has a quick ratio of 7.84, a current ratio of 8.81 and a debt-to-equity ratio of 0.44. The firm has a market cap of $7.18 billion, a PE ratio of -18.31 and a beta of 2.19. The firm’s 50 day moving average is $84.98 and its 200-day moving average is $113.02.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.35). The firm had revenue of $99.04 million for the quarter, compared to analysts’ expectations of $98.49 million. Sarepta Therapeutics had a negative net margin of 169.87% and a negative return on equity of 53.47%. The business’s quarterly revenue was up 26.2% on a year-over-year basis. During the same period in the previous year, the company posted ($1.15) EPS. On average, analysts forecast that Sarepta Therapeutics Inc will post -4.94 earnings per share for the current year.

In related news, Director Richard Barry purchased 5,000 shares of the business’s stock in a transaction on Friday, September 13th. The shares were bought at an average price of $87.49 per share, with a total value of $437,450.00. Following the completion of the purchase, the director now directly owns 3,183,756 shares in the company, valued at approximately $278,546,812.44. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael W. Bonney purchased 2,000 shares of the business’s stock in a transaction on Monday, September 9th. The shares were bought at an average cost of $86.74 per share, for a total transaction of $173,480.00. Following the purchase, the director now owns 7,051 shares of the company’s stock, valued at $611,603.74. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 18,200 shares of company stock worth $1,780,730. 6.60% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of the business. Janney Montgomery Scott LLC raised its stake in Sarepta Therapeutics by 2.7% during the second quarter. Janney Montgomery Scott LLC now owns 4,078 shares of the biotechnology company’s stock worth $620,000 after purchasing an additional 109 shares during the period. Nisa Investment Advisors LLC grew its holdings in Sarepta Therapeutics by 10.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,325 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 125 shares in the last quarter. World Asset Management Inc grew its holdings in Sarepta Therapeutics by 6.1% during the 2nd quarter. World Asset Management Inc now owns 2,312 shares of the biotechnology company’s stock valued at $351,000 after purchasing an additional 132 shares in the last quarter. BB&T Corp grew its holdings in Sarepta Therapeutics by 3.4% during the 2nd quarter. BB&T Corp now owns 4,405 shares of the biotechnology company’s stock valued at $669,000 after purchasing an additional 143 shares in the last quarter. Finally, Clarus Wealth Advisors grew its holdings in Sarepta Therapeutics by 9.0% during the 2nd quarter. Clarus Wealth Advisors now owns 1,816 shares of the biotechnology company’s stock valued at $276,000 after purchasing an additional 150 shares in the last quarter. 92.41% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

Recommended Story: Why do analysts give a neutral rating?

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.